|
1
|
Shields DJ, Agellon LB and Vance DE:
Structure, expression profile and alternative processing of the
human phosphatidylethanolamine N-methyltransferase (PEMT)
gene. Biochim Biophys Acta. 1532:105–114. 2001.PubMed/NCBI
|
|
2
|
Vance DE, Li Z and Jacobs RL: Hepatic
phosphatidylethanolamine N-methyltransferase, unexpected roles in
animal biochemistry and physiology. J Biol Chem. 282:33237–33241.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Z, Agellon LB, Allen TM, et al: The
ratio of phosphatidylcholine to phosphatidylethanolamine influences
membrane integrity and steatohepatitis. Cell Metab. 3:321–331.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vance DE and Vance JE: Phospholipid
biosynthesis in eukaryotes. Biochemistry of lipids, lipoproteins
and membranes. 5th edition. Vance DE and Vance JE: Elsevier;
Amsterdam: pp. 213–244. 2008, View Article : Google Scholar
|
|
5
|
Bauer DE, Hatzivassiliou G, Zhao F,
Andreadis C and Thompson CB: ATP citrate lyase is an important
component of cell growth and transformation. Oncogene.
24:6314–6322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barger JF and Plas DR: Balancing
biosynthesis and bioenergetics: metabolic programs in oncogenesis.
Endocr Relat Cancer. 17:R287–R304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuhajda FP: Fatty acid synthase and
cancer: new application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dueck DA, Chan M, Tran K, et al: The
modulation of choline phosphoglyceride metabolism in human colon
cancer. Mol Cell Biochem. 162:97–103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dobrzyńska I, Szachowicz-Petelska B,
Sulkowski S and Figaszewski Z: Changes in electric charge and
phospholipids composition in human colorectal cancer cells. Mol
Cell Biochem. 276:113–119. 2005.PubMed/NCBI
|
|
10
|
Glunde K, Bhujwalla ZM and Ronen SM:
Choline metabolism in malignant transformation. Nat Rev Cancer.
11:835–848. 2011.PubMed/NCBI
|
|
11
|
Tessitore L, Dianzani I, Cui Z and Vance
DE: Diminished expression of phosphatidylethanolamine
N-methyltransferase 2 during hepatocarcinogenesis. Biochem J.
337:23–27. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flavin R, Peluso S, Nguyen PL and Loda M:
Fatty acid synthase as a potential therapeutic target in cancer.
Future Oncol. 6:551–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogino S, Nosho K, Meyerhardt JA, et al:
Cohort study of fatty acid synthase expression and patient survival
in colon cancer. J Clin Oncol. 26:5713–5720. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rossi S, Graner E, Febbo P, et al: Fatty
acid synthase expression defines distinct molecular signatures in
prostate cancer. Mol Cancer Res. 1:707–715. 2003.PubMed/NCBI
|
|
15
|
Shurbaji MS, Kalbfleisch JH and Thurmond
TS: Immunohistochemical detection of a fatty acid synthase (OA-519)
as a predictor of progression of prostate cancer. Hum Pathol.
27:917–921. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahiro T, Shinichi K and Toshimitsu S:
Expression of fatty acid synthase as a prognostic indicator in soft
tissue sarcomas. Clin Cancer Res. 9:2204–2212. 2003.PubMed/NCBI
|
|
17
|
Visca P, Sebastiani V, Botti C, et al:
Fatty acid synthase (FAS) is a marker of increased risk of
recurrence in lung carcinoma. Anticancer Res. 24:4169–4173.
2004.PubMed/NCBI
|
|
18
|
Cerne D, Zitnik IP and Sok M: Increased
fatty acid synthase activity in non-small cell lung cancer tissue
is a weaker predictor of shorter patient survival than increased
lipoprotein lipase activity. Arch Med Res. 41:405–409. 2010.
View Article : Google Scholar
|
|
19
|
Cerne D, Melkic E, Trost Z, Sok M and Marc
J: Lipoprotein lipase activity and gene expression in lung cancer
and in adjacent noncancer lung tissue. Exp Lung Res. 33:217–225.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trost Z, Sok M, Marc J and Cerne D:
Increased lipoprotein lipase activity in non-small cell lung cancer
tissue predicts shorter patient survival. Arch Med Res. 40:364–368.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sobin LH and Wittekind C: Lung and pleural
tumours. TNM Classification of Malignant Tumours. 6th edition. John
Wiley & Sons; Hoboken, NJ, USA: pp. 97–107. 2002
|
|
22
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC: World Health Organization Classification of
Tumours. Pathology and Genetics of Tumours of the Lung, Pleura,
Thymus and Heart. IARC Press; Lyon, France: 2004
|
|
23
|
Trost Z, Marc J, Sok M and Cerne D:
Increased apolipoprotein E gene expression and protein
concentration in lung cancer tissue do not contribute to the
clinical assessment of non-small cell lung cancer patients. Arch
Med Res. 39:663–667. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vance JE and Vance DE: Metabolic insights
into phospholipid function using gene-targeted mice. J Biol Chem.
280:10877–10880. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tessitore L, Sesca E and Vance DE:
Inactivation of phosphatidylethanolamine N-methyltransferase-2 in
aflatoxin-induced liver cancer and partial reversion of the
neoplastic phenotype by PEMT transfection of hepatoma cells. Int J
Cancer. 86:362–367. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
da Costa KA, Kozyreva OG, Song J, et al:
Common genetic polymorphisms affect the human requirement for the
nutrient choline. FASEB J. 20:1336–1344. 2006.PubMed/NCBI
|
|
27
|
Xu X, Gammon MD, Ziesel SH, et al: Choline
metabolism and risk of breast cancer in a population-based study.
FASEB J. 22:2045–2052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mulligan HD and Tisdale MJ: Effect of the
lipid-lowering agent bezafibrate on tumour growth rate in
vivo. Br J Cancer. 64:1035–1038. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hörl G, Wagner A, Cole LK, et al:
Sequential synthesis and methylation of phosphatidylethanolamine
promote lipid droplet biosynthesis and stability in tissue culture
in vivo. J Biol Chem. 286:17338–17350. 2011.PubMed/NCBI
|
|
30
|
Li Z and Vance DE: Phosphatidylcholine and
choline homeostasis. J Lip Res. 49:1187–1194. 2008. View Article : Google Scholar
|
|
31
|
Qi C, Park JH, Gibbs TC, et al:
Lysophosphatidic acid stimulates phospholipase D activity and cell
proliferation in PC-3 human prostate cancer cells. J Cell Physiol.
174:261–272. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foster DA and Xu L: Phospholipase D in
cell proliferation and cancer. Mol Cancer Res. 1:789–800.
2003.PubMed/NCBI
|
|
33
|
Stewart JD, Marchan R, Lesjak MS, et al:
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell
migration and metastasis. Proc Natl Acad Sci USA. 109:8155–8160.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cao MD, Döpkens M, Krishnamachary B, et
al: Glycerophosphodiester phosphodiesterase domain containing 5
(GDPD5) expression correlates with malignant choline phospholipid
metabolite profiles in human breast cancer. NMR Biomed.
25:1033–1042. 2012. View
Article : Google Scholar
|
|
35
|
Kang DW, Choi KY and Min do S:
Phospholipase D meets Wnt signaling: a new target for cancer
therapy. Cancer Res. 71:293–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Awwad HM, Geisel J and Obeid R: The role
of choline in prostate cancer. Clin Biochem. 45:1548–1553. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ackerstaff E, Glunde K and Bhujwalla ZM:
Choline phospholipid metabolism: a target in cancer cells? J Cell
Biochem. 90:525–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mashima T, Seimiya H and Tsuruo T: De novo
fatty-acid synthesis and related pathways as molecular targets for
cancer therapy. Br J Cancer. 100:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nomura K, Noguchi Y and Matsumoto A:
Stimulation of decreased lipoprotein lipase activity in the
tumour-bearing state by the antihyperlipidemic drug bezafibrate.
Surg Today. 26:89–94. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mutoh M, Niho N and Wakabayashi K:
Concomitant suppression of hyperlipidemia and intestinal polyp
formation by increasing lipoprotein lipase activity in
Apc-deficient mice. Biol Chem. 387:381–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiménez-López JM, Carrasco MP, Segovia JL
and Marco C: Hexadecylphosphocholine inhibits phosphatidylcholine
synthesis via both the methylation of phosphatidylethanolamine and
CDP-choline pathways in HepG2 cells. Int J Biochem Cell Biol.
36:153–161. 2004.PubMed/NCBI
|
